BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

被引：0
|
作者：
Hao, Xiaoyao
Li, Hongyan
Liu, Xiaodong F.
Liu, Jinyu
Dai, Wenwen
Pan, Ying
Hu, Hui-Han
Li, Jun
Xia, Shukai
Lyu, Qun
Davis, Hugh M.
Chen, Mingjiu
Peng, Zeyu
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3135
引用
收藏
页数：2
相关论文
共 50 条
  • [1] BSI-507, a first-in-class bispecific antibody targeting PD1 and PVRIG for cancer immunotherapy
    Peng, Zeyu
    Liu, Xiaodong F.
    Li, Hongyan
    Dai, Wenwen
    Liu, Jinyu
    Hao, Xiaoyao
    Xia, Shukai
    Lv, Qun
    Davis, Hugh M.
    Chen, Mingjiu
    Ma, Mark Z.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
    Chen, Yi-Li
    Cui, Yue
    Liu, Xinyuan
    Liu, Guojian
    Dong, Xingchen
    Tang, Lei
    Hung, Yifeng
    Wang, Chunhe
    Feng, Mei-Qing
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 297 (06)
  • [3] Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
    Zhong, Zhenwei
    Zhang, Mengyao
    Ning, Yanan
    Mao, Guanchao
    Li, Xiaopei
    Deng, Qi
    Chen, Xiaorui
    Zuo, Dongliang
    Zhao, Xiangyu
    Xie, Ermin
    Wang, Huajing
    Guo, Lina
    Li, Bohua
    Xiao, Kai
    He, Xiaowen
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
    Zhenwei Zhong
    Mengyao Zhang
    Yanan Ning
    Guanchao Mao
    Xiaopei Li
    Qi Deng
    Xiaorui Chen
    Dongliang Zuo
    Xiangyu Zhao
    Ermin Xie
    Huajing Wang
    Lina Guo
    Bohua Li
    Kai Xiao
    Xiaowen He
    Scientific Reports, 12
  • [5] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
    Li, Tianye
    Niu, Mengke
    Zhou, Jianwei
    Wu, Kongming
    Yi, Ming
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [6] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
    Tianye Li
    Mengke Niu
    Jianwei Zhou
    Kongming Wu
    Ming Yi
    Cell Communication and Signaling, 22
  • [7] Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
    Li, Tianye
    Wang, Xinrun
    Niu, Mengke
    Wang, Mingli
    Zhou, Jianwei
    Wu, Kongming
    Yi, Ming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [9] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy.
    Chaudhary, Amit K.
    Shi, Jiadong
    Cai, Wenyan
    Wang, Bo
    Zaman, Mohd S.
    Huang, Cai
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Dong, Jianbo
    Liu, Yue
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2
    Yao, Yuan
    Ren, Yanan
    Hou, Xingguo
    Wang, Pei
    Zhu, Jinyu
    Liu, Song
    Ma, Xiaokun
    Liu, Teli
    Yang, Zhi
    Zhu, Hua
    Li, Nan
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 52 (01) : 36 - 47
12345